Alvogen Poland Sp. z.o.o.

ul. Kniaznina 4a
01-607 Warszawa
NIP: 7792393130 

+48 22 460 92 00
+48 22 869 07 15

Alvogen’s operations in Poland started in July 2011. The office is situated in Warsaw, capital of Poland. Dariusz Glogowski is the country manager for Alvogen Poland. Dariusz has a strong background of 20 years in the pharmaceutical industry. The office currently has 12 employees together with Regulatory & Pharmacovigilance expert, Sales & Marketing Manager, experienced hospital key accounts, person responsible for tenders, Finance and Administration Manager and Office Assistant. The local team is well positioned to build Alvogen presence in Poland, leveraging on a strong global product pipeline.

With 38 million inhabitance, Poland is 3rd biggest population in CEE (after Russia and Ukraine). At around 11.8 billion USD market, Poland is second biggest pharmaceutical market in CEE (after Russia).

Polish pharmaceutical market is covered mostly with generics – 80% volume, but they represent less than 30% of the value of drugs sold. Total yearly healthcare costs are calculated as 35 billion USD (7% GDP). There are approximately 80.000 doctors, 180.000 nurses and over 20.000 pharmacists working in Polish healthcare system.

Market info

Poland is in second place in Europe (after France) in terms of drug consumption in volume terms. An average Pole consumes about 30 packs per year. Such high consumption generates a high public spending on medicines.

Polish pharmaceutical market is characterized by a significant share of generic drugs (in this respect Poland stands out from other European countries). In value terms, generics account for 65% of the market (86.5%).

  • $11.8BPolish Pharmaceutical
    Market in 2011
  • 86.5%Generics market growth
    in volume 2011
  • 38.1 mlnPoland – population
  • $55.1BHealthcare budget in
    millions by 2016